Year: 2014

TORONTO, ONTARIO — (December 18, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to announce the expansion of its Clinical Advisory Board with the appointment of Canadian rheumatologist J. Carter Thorne, MD, FRCP(C), FACP, Chief of the Division of Rheumatology and Director of The Arthritis Program at Southlake … Continued

TORONTO, ONTARIO — (December 16, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF) today announced that they have, subject to approval by securities regulators, entered into an Investor Relations Consulting Agreement with Stonegate Capital Partners Inc. (“Stonegate”) based in Dallas, Texas. Under the terms of the agreement Stonegate will receive … Continued

TORONTO, ONTARIO — (November 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) filed its financial and operating results today for its fiscal quarter ended September 30, 2014. Highlights for the quarter include: • The Company completed the first stage of its Phase I study, the prescheduled SAD (single ascending dose) stage, … Continued

TORONTO, ONTARIO — (November 25, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report results from animal proof-of-concept studies on ATB-352, which is the second drug in the Company’s pipeline, as described in the CEO Letter of April 2014. These studies have demonstrated that ATB-352 potently inhibits … Continued

TORONTO, ONTARIO — (October 6, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report that the pre-scheduled single ascending dose portion of its Phase I program has been completed and has reached its primary objectives of safety and tolerability of ATB-346, up to the maximum dose tested … Continued

TORONTO, ONTARIO — (October 3, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE; OTCQX: ATBPF) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders of the Corporation held on October 1, 2014. The matters voted upon at the meeting and the results … Continued

TORONTO, ONTARIO — (September 15, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that, as of today, common shares of the Corporation began trading in the United States on the OTCQX exchange under the ticker symbol “ATBPF”. Antibe’s common shares will continue to trade on the … Continued

TORONTO, ONTARIO — (September 5, 2014) — Antibe Therapeutics Inc.’s Founder and Chief Scientific Officer, Dr. John Wallace, is the senior author of an article published this week in the prestigious scientific journal Proceedings of the National Academy of Science USA describing research that may lead to a significant improvement in the treatment of Crohn’s … Continued

TORONTO, ONTARIO — (August 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) filed its financial and operating results today for its fiscal quarter ended June 30, 2014. Highlights for the quarter include: Conducted non-brokered private placements yielding gross proceeds of $1,244,560, which together with financings closed in fiscal Q4 2014, is … Continued

TORONTO, ONTARIO — (July 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) filed its financial and operating results today for the fourth quarter and the year ended March 31, 2014. Antibe’s highlights for the fiscal year included: Successfully closing its initial public offering and listing on the TSX Venture Exchange. Achieving … Continued

TORONTO, ONTARIO — (July 17, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce the formation of its Clinical Advisory Board with the appointment of three distinguished, internationally recognized gastroenterologists. The three appointees are: Dr. Francis Chan, Professor of Medicine at The Chinese University of Hong Kong; Dr. Angel … Continued

TORONTO, ONTARIO — (June 26, 2014) — Antibe Therapeutics Inc. (TSXV: ATE) announced today that following the receipt of a No Objection Letter from Health Canada last week, its Phase I clinical trial was initiated today. This first clinical study of ATB-346, a drug with the promise of being a safer, anti-inflammatory painkiller, involves safety … Continued

TORONTO, ONTARIO — (June 19, 2014) — Antibe Therapeutics Inc. (TSXV: ATE) is pleased to announce that it has received regulatory approval to begin its Phase I clinical trial program. Health Canada issued a ‘No Objection Letter’ in response to Antibe’s Clinical Trial Application allowing the company to initiate its study entitled ‘A Double-Blind, Placebo-Controlled, … Continued

TORONTO, ONTARIO — (May 21, 2014) — Antibe Therapeutics Inc. (TSXV: ATE) is pleased to announce the submission of a Clinical Trial Application (“CTA”) to Health Canada for its lead drug, ATB-346. The CTA proposes the initiation of a clinical study entitled “A Double-Blind, Placebo-Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of … Continued

TORONTO, ONTARIO — (May 12, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce the appointment of Samira Sakhia (B.Comm., MBA, CPA) to its Board of Directors. Ms. Sakhia has been the CFO of Paladin Labs Inc. since 2002, where she is responsible for leading the finance, operations, human … Continued

To my fellow Shareholders, With our 2013-2014 fiscal year completed, I want to take a few moments to reflect on the past twelve months and to outline our plans for the year ahead. In the last year, we completed our transformation from a private, research-focused, drug-discovery venture into a publicly-traded, commercialization-focused, clinical stage drug development … Continued

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (April 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) has completed the third and final closing of its previously … Continued

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (April 7, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) has completed a second closing of its previously announced non-brokered … Continued

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (April 1, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces that discussions with the potential Latin American partner with … Continued

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (March 31, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) has closed its previously announced non-brokered private placement raising gross … Continued

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (March 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce, based on increased inbound demand, that … Continued

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (March 21, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces its intention to complete a non-brokered private placement of … Continued

TORONTO, ONTARIO — (March 17, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce that it has completed its planned pre-clinical program for its lead product ATB-346 to support initial clinical studies in humans. ATB-346 targets the global need for a GI-safe anti-inflammatory painkiller, a growing market that currently … Continued

TORONTO, ONTARIO — (March 4, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce that following the annual review by the Compensation Committee of the performance of the Corporation and the compensation practices of its peer companies, all personnel including Officers have been granted a 5% pay increase, and … Continued

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (January 28, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) is pleased to announce that it has completed the final … Continued

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. TORONTO, ONTARIO — (January 24, 2014) — Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV: ATE) announces an increase to the size of its non-brokered private … Continued